Amylyx Pharmaceuticals $AMLX stock is testing lower uptrend channelUptrend and downtrend channel patterns are technical analysis tools used to identify potential future price movements. They are formed by two parallel lines on a chart and can be u... wall support in the wake of regulatory approval of its oral treatment for ALS.
Amylyx Pharmaceuticals $AMLX Stock Technical Analysis
Amylyx Pharmaceuticals $AMLX stock is in a technical strong uptrend. The stock is trading in an uptrend channel and is testing lower channel wall support on November 18, 2022. The MACDThe MACD indicator is essentially a momentum indicator that shows the relationship between two different moving averages of price. The MACD is the difference between the 12-period ... is improving, but the money flow is still negative.
Amylyx Pharmaceuticals Q3 2022 Financial Results
Amylyx Pharmaceuticals reported financial results for the quarter ended September 30, 2022. The company reported an EPS and big revenueThe income statement provides a summary of a company's revenue and expenses over a specified period of time, typically a year or a quarter. It shows the company's total revenue, th... beat. Amylyx reported Q3 EPS of (92c) versus the consensus estimate of (97c). The company reported Q3 revenue of $345K versus the consensus estimate of $80K.
“The third quarter has proven to be a transformative time for Amylyx and the ALS community, marked by the regulatory approval of our new oral therapy for the treatment of ALS in the United States and commercial availability of our first product in Canada,” said Joshua Cohen and Justin Klee, Co-CEOs. “We are thrilled that RELYVRIO and ALBRIOZA are now available to people living with ALS in the U.S. and Canada, and we are encouraged by the early trajectory of enrollment in our Amylyx Care Team (ACT) Support Program as well as the rate of new prescriptions for this important new therapeutic option. We continue to work expeditiously during the early stages of our commercial launch to ensure every eligible person living with ALS will gain access as quickly and efficiently as possible.”